Pharmacological effects of gastric inhibitory polypeptide, cholecystokinin, and somatostatin on the serum levels of cationic trypsin-like immunoreactivity in man.
In six healthy volunteers there were no significant changes during a 300-min control period, whereas gastric inhibitory polypeptide in pharmacological doses first caused a transient and non-significant decrease and then a significant increase in the serum cationic trypsin-like immunoreactivity (CTLI). In another two groups of six healthy subjects, pharmacological doses of cholecystokinin elicited a non-significant increase, whereas somatostatin in pharmacological doses first caused a significant decrease and then a rebound effect with significantly higher levels of serum CTLI.
Florholmen
J
J
Burhol
P G
PG
Jenssen
T G
TG
Jorde
R
R
D000328:Adult; D002766:Cholecystokinin / Q000494:pharmacology*; D005260:Female; D005749:Gastric Inhibitory Polypeptide / Q000494:pharmacology*; D006801:Humans; D008297:Male; D010186:Pancreatic Function Tests; D013004:Somatostatin / Q000494:pharmacology*; D014357:Trypsin / Q000097:blood*
D013004:Somatostatin; D005749:Gastric Inhibitory Polypeptide; D002766:Cholecystokinin; D014357:Trypsin